N-AVD or BrECADD for Advanced-Stage Classical Hodgkin Lymphoma: Choosing the Right Treatment for the Right Patient.
Two different chemotherapy regimens for advanced Hodgkin lymphoma suit different patients based on age, fertility concerns, and heart/immune safety—not one fits all.
This review translates two landmark Phase III trials into an individualized clinical decision framework for advanced-stage classical Hodgkin lymphoma, clarifying that N-AVD and BrECADD target different patient profiles and risks rather than being head-to-head competitors. Key differentiators include hematologic toxicity, fertility, immune-related adverse events, PET availability, and patient age.
What the study was
- Study design
- Clinical decision review synthesizing and comparing two Phase III trials (SWOG S1826: N-AVD and GHSG HD21: BrECADD) for advanced-stage classical Hodgkin lymphoma
- Population
- Adults with advanced-stage classical Hodgkin lymphoma including patients >60 years
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Clinical Lymphoma, Myeloma & Leukemia
Why it surfaced
Practical individualized decision guide for two Phase III-validated frontline Hodgkin lymphoma regimens; timely for clinical practice as both N-AVD and BrECADD become standard options.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.